Novartis Acquires Avidity Biosciences for $12 Billion
Novartis has agreed to acquire Avidity Biosciences in a deal worth $12 billion, aiming to accelerate the development of late-stage treatments for muscular dystrophy.
The acquisition centers on Avidity's antibody-oligonucleotide conjugate (AOC) platform, which delivers RNA therapy by attaching an oligonucleotide to an antibody, targeting specific cells to modulate genetic activity.
The core of the acquisition is Avidity’s innovative technology.
- Acquisition worth: $12 billion
- Target: Muscular dystrophy treatments
- Key technology: Antibody-oligonucleotide conjugate (AOC) platform
Author's summary: Novartis acquires Avidity for $12B to boost RNA therapy.